ZhenFund Angel Portfolio Company "Xellaris" Closes Over RMB 200 Million Series A Round, Defining a New Paradigm for AI Drug Discovery with 3D Biological Intelligence
To bring more breakthrough therapies to patients worldwide.
Recently, Xellar Biosystems announced the completion of a Series A financing round exceeding RMB 200 million. The funds will be primarily directed toward building next-generation biological intelligence infrastructure centered on humanized models and mechanistic research — including expanding its organ-on-chip disease model portfolio, establishing a scalable mechanistic research platform, and continuing high-throughput, standardized collection of real-world biological data. In 2022, ZhenFund participated in the company's angel round.
Building on this foundation, the company will accelerate development of its AI platform driven by proprietary 3D wet-lab data, integrating multimodal data modeling, computer vision, and knowledge graphs to achieve a closed-loop flywheel of "data generation — mechanism analysis — model training — experimental validation," gradually constructing a 3D Bio Intelligence system based on "real-world data + virtual cells" with dynamic characterization and predictive capabilities, enabling digital reconstruction and mechanistic inference of complex biological processes.
Xellar Biosystems is an AI for 3D Biology platform company built on organ-on-chip technology, deeply integrating artificial intelligence, automation, and high-throughput experimental systems. It is dedicated to reconstructing the next paradigm of drug discovery by faithfully simulating human physiology and disease states. The company's platform enables standardized, reproducible, and quantifiable data generation under conditions closer to real human biology, with AI models that continuously learn and iterate to significantly enhance predictive accuracy and R&D efficiency in drug development.
Currently, Xellar Biosystems has established long-term partnerships with multiple global top-tier pharmaceutical companies, consumer health, and beauty conglomerates, with related business maintaining rapid growth over the past year. The company has achieved stable deployment across key application scenarios including drug safety evaluation, disease model construction, and compound efficacy validation, gradually forming a sustainable business model centered on platform capabilities, standard systems, and data assets.
On the regulatory and international standards front, Xellar Biosystems' organ-on-chip platform began collaborating with 3Rs organizations and the FDA in 2023, and this January was formally accepted by the U.S. Food and Drug Administration into the review pathway of its Innovation and Science Advancement Program — positioning it to become among the first drug development tools globally to receive FDA scientific recognition and qualification. Under this pathway, once the technology completes regulatory validation, it can be directly used by pharmaceutical companies as a compliant tool in new drug development and enter IND filing and subsequent development processes, significantly reducing uncertainty and redundant experimental costs in drug R&D. This milestone signals that Xellar Biosystems' platform capabilities are accelerating from R&D tools toward regulatory-recognized infrastructure-grade capabilities.
Following this financing round, Xellar Biosystems will continue increasing investment in AI and computational team building, driving coordinated development of multimodal biological data modeling, predictive models, and large model capabilities. Simultaneously, the company will further advance industrial deployment of its automated experimental platform, achieving highly standardized and scalable organ-on-chip experiment execution and data collection, while systematically constructing knowledge graphs linking organ-on-chip technology with disease mechanisms, drug efficacy and toxicity, and biological pathways — laying the data foundation for the next phase of larger-scale intelligent decision-making and pipeline co-development.
Xin Xie, founder and CEO of Xellar Biosystems, stated that this financing round represents important validation of our "AI for 3D Biology" platform strategy and team execution. "Post-financing, we will fully commit to expanding our AI computational team, scaling deployment of our automation systems, and building out multimodal knowledge graphs, continuously strengthening our technical moat. The synchronized progress with regulatory agencies in both China and the U.S. marks our platform's evolution toward industry infrastructure with regulatory recognition. We will work with partners to accelerate deep application of '3D Bio Intelligence' across all stages of new drug development, tangibly reducing R&D costs and risks, and bringing more breakthrough therapies to patients worldwide."
氦星光联｜Yahaha｜思谋科技 完美日记｜井英科技｜Hesai Technology
优艾智合｜零零科技｜壹悟科技 怒喵科技｜KnowYourself｜留形科技 奥创光年｜Xiaohongshu｜黑湖科技｜元古
与光科技｜星测未来｜清越科技 CellX｜云洲智能｜固纳科技 鼎茂科技｜未名拾光｜耀速科技
